Sygnature Chemical Services Ltd., a leading UK-based provider of premium discovery chemistry services to the global pharmaceutical industry, today announced that it has been selected by the University of Leicester to support a Wellcome Trust Seeding Drug Discovery Initiative (SDDI)-funded research programme.  Under the terms of the agreement, Sygnature will provide synthetic, medicinal and computational chemistry services to help Leicester identify new treatments for the serious neurological handicaps associated with invasive pneumococcal diseases.

“Sygnature has been chosen by the University of Leicester to provide discovery chemistry support to this important research project,” said Dr Simon Hirst, Sygnature’s CEO. “For the past 18 months, Sygnature has been supplying medicinal chemistry resource and expertise into a Wellcome Trust SDDI-funded project for another UK university. This has advanced well, and Sygnature’s selection for a second Wellcome Trust-funded project is a testament to the successful application of our know-how and expertise in medicinal and computational chemistry. I am confident that Sygnature will be able to make a significant contribution to the University of Leicester’s pneumococcal diseases programme.”